Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$7.65 - $15.51 $3 Million - $6.08 Million
-391,983 Reduced 97.17%
11,432 $168,000
Q3 2022

Nov 14, 2022

BUY
$8.63 - $15.52 $23,525 - $42,307
2,726 Added 0.68%
403,415 $3.57 Million
Q2 2022

Aug 22, 2022

BUY
$8.59 - $20.77 $285,763 - $690,955
33,267 Added 9.05%
400,689 $5.07 Million
Q1 2022

May 16, 2022

BUY
$15.52 - $35.65 $219,126 - $503,342
14,119 Added 4.0%
367,422 $6.95 Million
Q4 2021

Feb 14, 2022

BUY
$28.89 - $35.33 $353,989 - $432,898
12,253 Added 3.59%
353,303 $12.4 Million
Q3 2021

Nov 15, 2021

BUY
$35.66 - $42.94 $1.16 Million - $1.39 Million
32,434 Added 10.51%
341,050 $12.5 Million
Q2 2021

Aug 12, 2021

SELL
$23.7 - $39.27 $50,860 - $84,273
-2,146 Reduced 0.69%
308,616 $12.1 Million
Q1 2021

May 17, 2021

SELL
$27.01 - $36.8 $63,149 - $86,038
-2,338 Reduced 0.75%
310,762 $8.78 Million
Q4 2020

Feb 12, 2021

BUY
$27.51 - $34.36 $1.12 Million - $1.4 Million
40,681 Added 14.93%
313,100 $10 Million
Q3 2020

Nov 13, 2020

BUY
$25.8 - $34.61 $90,119 - $120,892
3,493 Added 1.3%
272,419 $8.8 Million
Q2 2020

Aug 14, 2020

BUY
$17.65 - $28.05 $92,362 - $146,785
5,233 Added 1.98%
268,926 $7.42 Million
Q1 2020

May 14, 2020

BUY
$15.19 - $29.51 $314,676 - $611,329
20,716 Added 8.53%
263,693 $4.71 Million
Q4 2019

Feb 13, 2020

SELL
$17.17 - $25.95 $240,465 - $363,429
-14,005 Reduced 5.45%
242,977 $6.09 Million
Q3 2019

Nov 13, 2019

BUY
$17.84 - $22.69 $97,763 - $124,341
5,480 Added 2.18%
256,982 $4.59 Million
Q1 2019

May 15, 2019

BUY
$21.27 - $30.58 $1.59 Million - $2.28 Million
74,700 Added 42.25%
251,502 $7.69 Million
Q4 2018

Feb 15, 2019

BUY
$23.09 - $37.69 $4.08 Million - $6.66 Million
176,802 New
176,802 $4.08 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.